Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vor Biopharma Inc.

0.8955
+0.07789.51%
Post-market: 0.8559-0.0396-4.42%19:59 EDT
Volume:271.79K
Turnover:235.67K
Market Cap:111.74M
PE:-0.54
High:0.9126
Open:0.8270
Low:0.8270
Close:0.8177
Loading ...

Company Profile

Company Name:
Vor Biopharma Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
168
Office Location:
100 Cambridgepark Drive,Suite 101,Cambridge,Massachusetts,United States
Zip Code:
02140
Fax:
- -
Introduction:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Kush M. Parmar
Chairman of the Board
Robert Ang
President, Chief Executive Officer and Director
Daniella Beckman
Director
David C. Lubner
Director
Joshua Resnick
Director
Matthew Patterson
Director
Sven Ante Lundberg
Director

Shareholders

Name
Position
Robert Ang
President, Chief Executive Officer and Director
Nathan Jorgensen
Chief Financial Officer
Christopher Slapak
Chief Medical Officer
Sadik Kassim
Chief Technology Officer
Tirtha Chakraborty
Chief Scientific Officer